Sayre therapeutics

At Sayre Therapeutics, we focus on bringing hitherto unavailable novel medicines, drug-delivery devices, companion diagnostics and diagnostic imaging agents to medical oncologists, surgical oncologists, radiation oncologists, interventional radiologists and rheumatologists

We facilitate access to differentiated medical solutions to patients and clinicians in emerging markets by identifying high unmet needs across the healthcare continuum. We engage with global partners and customers, enabling commercial innovations through strategy and superior science, to drive profitable growth.

Sayre Therapeutics was founded in 2015 backed by leading institutional investors.
The team boasts 25 years of global executive experience in leading Pharmaceutical, Medical Diagnostics & Devices companies. Sayre Therapeutics has been identified as a high potential healthcare company, a pedigree team with proven wins and a robust clinician network in the Oncology / Immunology space. The company is uniquely positioned with a first-mover advantage, which allows for it to quickly create a portfolio of differentiated global assets in emerging markets.

Sayre is backed by two leading venture capital firms (VCs).

Our geographic footprint covers India, South Asian and South-East Asian countries which are witnessing a high growth rate across the disease areas of interest. Sayre Therapeutics with its focused strategy, strong financial backing and established relationships with clinicians and regulatory know-how, will be nimble and to that end, will prove to be a committed partner to licensors for their global assets.

Oncology Drugs
Immunology Drugs
Molecular diagnostics
Novel Drug delivery devices
Cancer Drugs
Drugs for Breast Cancer
Drugs for chemotherapy